InfertilityPhase 4NCT00854373
Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial
A Phase 4 study testing Bravelle(follicle stimulating hormone) in people with Infertility, run by University of California, San Francisco at 1 site in United States.
Trial summary
Marcelle Cedars, M.D., Victor Fujimoto, M.D., Mitch Rosen, M.D., Heather Huddleston, M.D., Paolo Rinaudo, M.D., Anthony Dobson, M.D., and Shehua Shen, M.D. from the UCSF Department of Obstetrics and Gynecology and Reproductive Sciences are conducting a study to learn about ovarian stimulation and oocyte maturation to… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Infertility
- What is being tested?
- Bravelle(follicle stimulating hormone)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 232 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jun 2007to 20 Apr 2010
- Phase
- Phase 4
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patients undergoing in vitro fertilization
Who cannot join
- risk of ovarian hyperstimulation syndrome
Trial locations and contacts
1 site in 1 country.
About this study
Marcelle Cedars, M.D., Victor Fujimoto, M.D., Mitch Rosen, M.D., Heather Huddleston, M.D., Paolo Rinaudo, M.D., Anthony Dobson, M.D., and Shehua Shen, M.D. from the UCSF Department of Obstetrics and Gynecology and Reproductive Sciences are conducting a study to learn about ovarian stimulation and oocyte maturation to improve fertilization, embryo quality, implantation and clinical pregnancy rates in patients undergoing in vitro fertilization (IVF). Two hormones, follicle stimulating hormone and human chorionic gonadotropin (FSH/hCG) will be compared to the standard one hormone, hCG, for the ovulation trigger.
Over the past two decades, the success rate of assisted reproductive technology (ART) has dramatically increased. This increase has largely been attributed to improvements in the laboratory conditions and improvements in ovarian stimulation protocols (those medications used to increase the number of eggs maturing each cycle). Less work has been done on different ways to cause the final maturation of the eggs and the release of the egg from the ovary. The investigators propose to change the final injection prior to the egg retrieval (the ovulation trigger) so that it looks more like what happens in a normal menstrual cycle, where two hormones (both luteinizing hormone (LH) and FSH) increase. The investigators want to find out if this will improve egg quality and increase chances for pregnancy.
Read the detailed description
We observe during (In vitro fertilization) IVF, there are deviations in oocyte morphology and maturity within an individual cohort and that oocyte degeneration, and failed fertilization exist. Regardless, even if fertilization occurs, a large proportion of embryos fail to progress through the pre-implantation stages of development. In order for fertilization and embryo development to occur, the oocyte must mature or develop "competence". FSH may be a fundamental component to the final stages of oocyte maturation. Evidence suggests that with exogenous ovarian stimulation not all follicles achieve equal vascularity, and hence they are exposed to different amounts of FSH. We hypothesize FSH is required, within each follicle, at the time of ovulation trigger for oocyte maturation and prevention of atresia.
The ovarian stimulation prior to IVF attempts to mimic, and yet augment, normal physiology. The stimulation begins with gonadotropins to rescue antral follicles and stimulate growth. Subsequently hCG, which shares 80% homology with LH, is administered to facilitate maturation of the oocyte. However, the ovulatory phase in the normal menstrual cycle encompasses a concomitant LH and FSH prior to ovulation (see figure).
Maturation is a process whereby the oocyte undergoes changes in preparation for fertilization and embryo development. This entails both nuclear and cytoplasmic transformation. Nuclear maturation pertains to the resumption of meiosis to metaphase II (MII). It is well established that the LH surge is intimately involved in this process. Although the mechanism is not completely known, there are several steps. It is thought germinal vesicle breakdown requires a burst of calcium oscillations. During folliculogenesis, nuclear maturation of the oocyte is normally under tonic inhibition by a putative factor, oocyte-meiotic inhibitor (OMI). Some evidence suggests, prior to ovulation, LH inhibits the release of OMI from either the granulosa or theca cells. OMI likely acts as a paracrine factor and increases cAMP production in the granulosa cells (cumulus), which then acts as a messenger to the oocyte to maintain minimal calcium levels. In addition, LH is thought to decrease the gap junction communication between the cumulus and granulosa. Other evidence points to a putative signal that is synthesized by the granulosa cells, called follicular fluid meiotic activating substance. Both elements involved in nuclear maturation involve LH activity. The induction of LH receptors is via FSH. Under physiologic conditions there is a co-existent FSH surge with the LH surge. LH usually rises about 10 fold from baseline and FSH rises roughly 4 fold from baseline. It is possible that the surge of FSH ensures the required amount of LH receptors to complete nuclear maturation.
Cytoplasmic maturation is more difficult to identify. The process entails the synthesis of new proteins and post-translational modifications of existing proteins to allow for calcium activated pathways facilitating fertilization and embryo development. It is known that there is extensive cross-talk between the oocyte and granulosa cells. Few morphogenetic determinants of cytoplasmic maturation have been identified, but this remains an area of intense investigation From a clinical perspective, it is possible that FSH is required in this process of nuclear and/or cytoplasmic maturation, and that a minimal threshold of FSH may be required to maintain the gap junctions for completion of oocyte development. This evidence may be further supported by in-vitro maturation studies that show that FSH has a stimulatory effect on cytoplasmic and nuclear maturation.
Oocyte degeneration (atresia) is observed in 5-15% of the oocytes at the time of, or after, intracytoplasmic sperm injection. The etiology of degeneration has not been determined. The fate of the oocyte is likely determined prior to oocyte retrieval. At the time of retrieval, the apoptotic process in oocytes destined to undergo atresia has probably already been initiated. Under physiologic conditions, the granulosa cells die prior to the oocyte. There is evidence that atretic follicles have a high androgen to estrogen ratio. It is likely an indication of the deteriorating health of the granulosa cells. It is known that FSH has potent anti-apoptotic activity (inhibition of atresia), and the mechanism may be indirect via estradiol production. There is evidence that FSH primed follicles can grow with LH administration, in spite of low FSH levels. However, observations have shown that this process favors large follicles and that in the smaller follicles a critical ratio of FSH activity to LH activity is needed for survival. In support of this theory, others have suggested there is a narrow therapeutic window for LH. If E2 production is not adequate, LH may be detrimental to the follicle. The LH surge might hasten this process, in those follicles with a relative lack of vascularity (and/or lack of maturity), by a massive development of androgens and a relative lack of aromatase activity.
- Conditions
- Infertility
- Being tested
- Bravelle(follicle stimulating hormone), Saline ( placebo)
- Keywords
- Infertility, Pregnancy, in vitro fertilization
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bravelle(follicle stimulating hormone)Drug
One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.
Saline ( placebo)Other
1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Bravelle Receives: Drug: Bravelle(follicle stimulating hormone) |
| 2 | Placebo comparator | Saline Receives: Other: Saline ( placebo) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Fertilization Proportion (2PN/Oocytes Collected)
Number of normally fertilized oocytes (2PNs) divided by the total number of oocytes collected (i.e., not just the number of inseminated metaphase II state (MII) oocytes). This accounted for the possibility of both an enhanced oocyte maturation and improved fertilization of the mature oocytes. This also permitted inclusion of both IVF and intracytoplasmic sperm injection (ICSI) cycles in a way that allowed for evaluation of collective fertilization rates (i.e., typically, the denominator in IVF in calculating fertilization rate is all eggs collected, but in ICSI it is calculated using only the number of MII oocytes injected).
Measured: 24 hours after IVF or intracytoplasmic sperm injection (ICSI)
Secondary outcomes (2)
Mature Oocyte Recovery Rate Percentage
Likelihood of obtaining an oocyte from a single mature-sized follicle on each ovary. Mature follicles are usually 17mm in diameter or greater.
Measured: From the ultrasound done on the HCG trigger date, until the oocyte retrieval time which is up to 36 hours after HCG administration
Clinical Pregnancy Rate Percentage
The percentage of participants that achieve a clinical pregnancy as confirmed by Fetal heart motion by transvaginal ultrasound
Measured: 6 weeks after embryo transfer
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2009 (estimated)
- Study start1 Jun 2007
- Primary completion20 Apr 2010
- Study completion20 Apr 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for InfertilityStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 232 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mitchell P Rosen, MD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00854373
- Sponsor's protocol ID
- MR-9999
- Status last verified
- Dec 2025
- First submitted
- 2 Mar 2009
- Last updated
- 12 Dec 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Lamb JD, Shen S, McCulloch C, Jalalian L, Cedars MI, Rosen MP. Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2011 Apr;95(5):1655-60. doi: 10.1016/j.fertnstert.2011.01.019.
PubMed 21315341